Drug
Linerixibat clinical trials
Also written GSK2330672.
Keep track of what changes. Save the linerixibat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses linerixibat is read from its arms, and is right about nine times in ten.
Testing it · 14
- J-LINX: Japan LINerixibat eXtension StudyNot yet recruitingPhase 3GlaxoSmithKlineNCT07860710Written as Linerixibat
- Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)CompletedPhase 3GlaxoSmithKlineNCT04950127Written as Linerixibat
- Linerixibat Long-term Safety, and Tolerability StudyActive, not recruitingPhase 3GlaxoSmithKlineNCT04167358Written as Linerixibat
- Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy ControlsCompletedPhase 1GlaxoSmithKlineNCT05393076Written as Linerixibat
- Food Effect Study of Linerixibat Tablets in Healthy Adult ParticipantsCompletedPhase 1GlaxoSmithKlineNCT05435170Written as linerixibat
- Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult ParticipantsCompletedPhase 1GlaxoSmithKlineNCT05133830Written as Linerixibat
- Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary CholangitisCompletedPhase 2GlaxoSmithKlineNCT02966834Written as GSK2330672
- Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy SubjectsCompletedPhase 1GlaxoSmithKlineNCT04053023Written as GSK2330672 (linerixibat)
- Pharmacokinetics (PKs) and Metabolism of Radiolabelled LinerixibatCompletedPhase 1GlaxoSmithKlineNCT03992014Written as Linerixibat tablet
- A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes PatientsCompletedPhase 2GlaxoSmithKlineNCT02202161Written as GSK2330672
- Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking MetforminCompletedPhase 2GlaxoSmithKlineNCT01929863Written as GSK2330672
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of PruritusCompletedPhase 2GlaxoSmithKlineNCT01899703Written as GSK2330672
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.CompletedPhase 1GlaxoSmithKlineNCT01607385Written as GSK2330672
- First Time in Human Study Using GSK2330672CompletedPhase 1GlaxoSmithKlineNCT01416324Written as 0.1 mg GSK2330672
Codes
What other systems call linerixibat · ClinicalTrials.gg INT002192
- MeSH (NLM) C000732018linerixibatOne source NLM
- UNII (FDA) 386012Z45SLINERIXIBATConfirmed FDA, NLM, Wikidata
- Wikidata Q27256749linerixibatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166652LinerixibatOne source FDA
- DrugBank DB11729One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000732018 | linerixibat | One source NLM |
| UNII (FDA) | 386012Z45S | LINERIXIBAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27256749 | linerixibat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166652 | Linerixibat | One source FDA |
| DrugBank | DB11729 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.